Lpath Inc (LPTN) 4.18 $LPTN
Traumatic Brain Injury - Pipeline Review, H1 2014: Includes 42 Company and 72 Drug Profiles
M2 - Mon May 12, 5:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vqxgvm/traumatic_brain) has announced the addition of the "Traumatic Brain Injury - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Traumatic Brain Injury, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Traumatic Brain Injury and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved: - ALSP, Inc. - Acorda Therapeutics, Inc. - Adamas Pharmaceuticals, Inc. - Allinky Biopharma - Amarantus Bioscience Holdings, Inc. - Athersys, Inc. - BHR Pharma, LLC - Bionature E.A. Ltd. - Cognosci, Inc. - Concert Pharmaceuticals, Inc. - D-Pharm Ltd. - Encore Therapeutics Inc. - Euroscreen S.A. - Grupo Ferrer Internacional, S.A. - Intellect Neurosciences, Inc. - Io Therapeutics, Inc. - Lixte Biotechnology Holdings, Inc. - Lpath, Inc. - M's Science Corporation - MAPREG - MandalMed, Inc. - Mnemosyne Pharmaceuticals, Inc. - NeoStem, Inc. - Neuralstem, Inc. - Neuren Pharmaceuticals Limited - NeuroHealing Pharmaceuticals Inc. - NeuroNascent, Inc. - NeuroVive Pharmaceutical AB - Omeros Corporation - Oxygen Biotherapeutics, Inc. Drug Profiles: - epoetin alfa - progesterone - progesterone - NeuroSTAT - Oxycyte - VAS-203 - NH-001 - NNZ-2566 - atorvastatin calcium - NeuroSTAT - glyburide - Allopregnanolone - VOLT-02 - SB-623 - RGS-2064 - DP-b99 - amantadine hydrochloride - Drug for Traumatic Brain Injury - MAP-4343 - Posiphen - MultiStem - Lpathomab - RGN-352 - cutamesine - INN-01 - NSI-189 - COG-1410 - AMR-001 - NSI-566 - LB-201 For more information visit http://www.researchandmarkets.com/research/vq...atic_brain
Lpath announces Fast-Track SBIR grant for IND-enabling studies of Lpathomab for Traumatic Brain Injury
M2 - Mon May 05, 8:14AM CDT
Antibody-platform company Lpath Inc (NasdaqCM:LPTN) said on Monday that it will receive a USD1.7m, 2.5-year grant to develop its antibody therapeutic, Lpathomab, which is directed against the bioactive lipid lysophosphatidic acid (LPA) for the treatment of traumatic brain injury (TBI).
Lpath Lands Fast-Track SBIR Grant from the NIH for Traumatic Brain Injury Treatment
PR Newswire - Mon May 05, 6:30AM CDT
Lpath, Inc. (NASDAQ: LPTN), the industry leader in bioactive lipid-targeted therapeutics, received official notification from the National Institutes of Neurological Diseases and Stroke (NINDS) that it has been awarded a $1.7 million, 2.5-year grant to develop its antibody therapeutic, Lpathomab(TM), which is directed against the bioactive lipid lysophosphatidic acid (LPA) for the treatment of traumatic brain injury (TBI).
Global Colitis Therapeutics Pipeline Review 2014 - Analysis of 16 Companies & 32 Drug Profiles
M2 - Tue Apr 29, 8:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3zwv5t/colitis) has announced the addition of the "Colitis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Colitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Colitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Colitis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Colitis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Colitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Colitis pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Colitis - Companies Involved in Therapeutics Development - Inovio Pharmaceuticals, Inc. - BioLineRx, Ltd. - Pfizer Inc. - Idera Pharmaceuticals, Inc. - Lpath, Inc. - Protalix BioTherapeutics, Inc. - Galapagos NV - Akebia Therapeutics, Inc. - NasVax Ltd. - Lycera Corp. - Zyngenia, Inc. - N30 Pharmaceuticals - Cognosci, Inc. - Atlantic Healthcare Limited - CellAct Pharma GmbH - Ajinomoto Pharmaceuticals Co., Ltd. Drug Profiles - LT-1009 - PF-06425090 - IMO-3100 - BL-5040 - VGX-1027 - N-6022 - GLPG-0634 - COG-112 - Anti-CD3 Oral Immunotherapy - etanercept biosimilar - N-6547 - BRA-101 - Bioenergetics Program - ARA-290 - CAP-2.1 - CAP-2.2 - Clostridium difficile Vaccine - Cathelicidin - IP-1510 - Helminth-Derived Peptides - Drugs to Inhibit Panx1 for Colitis - Recombinant Cholera Toxin-B - Bi-Specific Anti-TNFalpha/Ang2 Zybody - auranofin - NK-007 - Treg Cells to Inhibit TCR Antagonist for Colitis - Vaccine for Colitis and Respiratory Tract Inflammatory Disorders - APY-0201 - IL-23 P19 Vaccine - AKB-6899 For more information visit http://www.researchandmarkets.com/research/3zwv5t/colitis
Global Diabetic Neuropathy Therapeutic Pipeline Review 2014 - 11 Companies and 18 Drugs Profiled
M2 - Mon Apr 28, 2:56AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8552ww/diabetic) has announced the addition of the "Global Diabetic Neuropathy Therapeutic Pipeline Review 2014 - 11 Companies and 18 Drugs Profiled" report to their offering. This report provides comprehensive information on the therapeutic development for Diabetic Neuropathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Neuropathy and special features on late-stage and discontinued projects.The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. Scope: - The report provides a snapshot of the global therapeutic landscape of Diabetic Neuropathy - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Diabetic Neuropathy and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Diabetic Neuropathy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages Companies Involved in Therapeutics Development: - Dainippon Sumitomo Pharma Co., Ltd. - Neuralstem, Inc. - Lpath, Inc. - DiaMedica Inc. - R-Tech Ueno, Ltd. - Neurotune AG - Intellect Neurosciences, Inc. - Glucox Biotech AB - Vascular Pharmaceuticals, Inc. - Relmada Therapeutics, Inc. - Dong-A Socio Holdings Co Ltd Drug Profiles: - ranirestat - ranirestat - DA-3030 - DA-9801 - atexakin alfa - Lpathomab - NT-13317 - RTU-1096 - INN-01 - NSI-566 - mepivacaine hydrochloride - Stromal Cell Therapy For Diabetic Complications - VPI-2690-B - Angiotensin (1-7) peptide - Small Molecule For Diabetic Neuropathy And Retinopathy - DM-433 - Small Molecule To Inhibit NOX-4 For Diabetic Neuropathy - BBI-21007 For more information visit http://www.researchandmarkets.com/research/8552ww/diabetic
Lpath and Walter Reed Army Institute for Research Begin Efficacy Study Using Lpathomab in Traumatic Brain Injury Models
PR Newswire - Wed Apr 23, 6:30AM CDT
Lpath, Inc. (NASDAQ: LPTN), the industry leader in bioactive lipid-targeted therapeutics, and scientists from the Center for Military Psychiatry and Neuroscience, Walter Reed Army Institute of Research (WRAIR), have initiated a study that is the focus of a collaborative research agreement.
3 Stocks Under $10 to Watch
at The Street - Mon Mar 17, 6:40AM CDT
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
Nasdaq stocks posting largest volume increases
AP - Thu Mar 06, 5:07PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
New Published Paper Shows Efficacy of Lpath's Anti-LPA Antibody, Lpathomab, in Traumatic Brain Injury Models
PR Newswire - Wed Mar 05, 6:30AM CST
Lpath, Inc. (NASDAQ: LPTN), the industry leader in bioactive lipid-targeted therapeutics, has brought scientists one step closer to finding a potential treatment for traumatic brain injury (TBI) with a recent publication showing that Lpathomab(TM), a therapeutic antibody, reverses much of the damage caused by trauma to the nervous system.
Lpath to Present at Upcoming Roth Investor Conference
PR Newswire - Tue Mar 04, 7:00AM CST
Lpath, Inc. (NASDAQ: LPTN), the industry leader in bioactive lipid-targeted therapeutics, today announced that Scott Pancoast, president and CEO, will be presenting at the 26th Annual Roth Conference being held March 10 -12, 2014 in Laguna Niguel, Calif. Mr. Pancoast is scheduled to present on March 11, 2014 at 4:30 p.m. PST/7:30 p.m. EST. The presentation will be webcast live and will be available for replay on the Lpath, Inc. corporate website at www.Lpath.com.
Lpath announces receipt of key US patent related to its ocular drug programme
M2 - Thu Jan 23, 5:03AM CST
Lpath Inc (Nasdaq:LPTN), a provider of bioactive lipid-targeted therapeutics, announced on Wednesday the receipt of official notification from the US Patent and Trademark Office that it has been issued another key patent supporting its iSONEP programme.
Lpath Granted Key U.S. Patent Related to Ocular Drug Program, iSONEP
PR Newswire - Wed Jan 22, 6:30AM CST
Lpath, Inc. (NASDAQ: LPTN), the industry leader in bioactive lipid-targeted therapeutics, received official notification from the U.S. Patent and Trademark Office that the company has been issued another key patent supporting its iSONEP(TM) program. The newly issued U.S. patent, No. 8,614,103, is entitled, "Compositions and Methods for Treating Ocular Conditions." It claims methods of using monoclonal antibodies (including iSONEP) that bind sphingosine-1-phosphate (S1P) in the treatment of a wide variety of ocular conditions, including wet age-related macular degeneration (AMD).
FEPSGA Games - Herbalist, Others Enjoy Trade Boom in Makurdi
All Africa Global Media - Wed Dec 18, 4:41AM CST
A herbalist selling traditional medicines at the venue of the ongoing Federal Public Service Games Association (FEPSGA) Games in Makurdi says he is enjoying high patronage.
Global Pulmonary Fibrosis Pipeline Review Report - H2 2013 Edition Now Available
M2 - Tue Dec 17, 10:01AM CST
Research and Markets (http://www.researchandmarkets.com/research/cqb72k/pulmonary) has announced the addition of the "Pulmonary Fibrosis - Pipeline Review, H2 2013" report to their offering. 'Pulmonary Fibrosis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Pulmonary Fibrosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Pulmonary Fibrosis. Scope - A snapshot of the global therapeutic scenario for Pulmonary Fibrosis. - A review of the Pulmonary Fibrosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Pulmonary Fibrosis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Involved in Pulmonary Fibrosis Therapeutics Development - Eli Lilly and Company - Lpath, Inc. - Mesoblast Ltd - NicOx SA - Oncothyreon Inc - Pharmaxis Ltd. - Paloma Pharmaceuticals, Inc. - Digna Biotech, S.L. - Aquinox Pharmaceuticals Inc. - Angion Biomedica Corp. - Centocor Ortho Biotech, Inc. - Fibrotech Therapeutics Pty. Ltd. - FCB-Pharmicell Co.,Ltd. - Clarassance, Inc. Drug Profiles - Lpathomab - P-17 - AZX-100 - PX-866 - STNM-04 - P-529 - AQX-1125 - Btx-201 - GR-MD-02 - ICG-001 - CG-1011 - ANG-3298 - C-201 - Galectin-3 Inhibitors - SDP-051 - FT-011 - CT-140 - PDE-4A4 Inhibitors - NCX-466 - MC-1575 - Lungcellgram - CpG Oligonucleotides - PXS-5033-A For more information visit http://www.researchandmarkets.com/research/cqb72k/pulmonary
Lpath Withdraws From Pfizer's Process to Assign iSONEP Rights
PR Newswire - Thu Dec 12, 6:00AM CST
Lpath, Inc. (Nasdaq: LPTN), the category leader in lipid-targeted therapeutics, is no longer actively participating in Pfizer's process to assign the exclusive option it has for a worldwide license to develop and commercialize Lpath's iSONEP(TM). Pfizer has informed Lpath that its offers were not competitive with other offers.
Lpath Announces New Antibody Program, Altepan(TM), Targeting Respiratory Disease
PR Newswire - Thu Nov 21, 6:00AM CST
Lpath, Inc. (Nasdaq: LPTN), the category leader in lipid-targeted therapeutics, has used its proprietary discovery technology to generate several monoclonal antibody product candidates targeting the leukotriene family of bioactive lipids. Leukotrienes are implicated in numerous inflammatory processes. The lead antibody, which binds to and neutralizes several different leukotriene isoforms, has shown positive in vivo results, and testing in animal models of respiratory disease, including asthma, is now underway.
Macular Degeneration - Pipeline Review, H2 2013 Gives an Overview of Pipeline Products for Macular Degeneration
M2 - Wed Sep 04, 12:19PM CDT
Research and Markets (http://www.researchandmarkets.com/research/wv3x9q/macular) has announced the addition of the "Macular Degeneration - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Macular Degeneration - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Macular Degeneration, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Macular Degeneration. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Macular Degeneration. - A review of the Macular Degeneration products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Macular Degeneration pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: Normal 0 false false false MicrosoftInternetExplorer4 Alcon, Inc. Genzyme Corporation Johnson & Johnson F. Hoffmann-La Roche Ltd. Bausch & Lomb Incorporated Allergan, Inc. Shionogi & Co., Ltd. pSivida Corp. Advanced Cell Technology, Inc. GlaxoSmithKline plc Genentech, Inc. Quark Pharmaceuticals, Inc. Pfizer Inc. iCo Therapeutics Inc. Lpath, Inc. Mesoblast Ltd BioDiem Ltd Summit Corporation plc ThromboGenics NV PolyMedix, Inc. e-Therapeutics plc NanoCarrier Co., Ltd. R-Tech Ueno, Ltd. Intellect Neurosciences, Inc. Omeros Corporation Angstrom Pharmaceuticals, Inc. Targa Therapeutics Corp. Pfenex Inc. SelectX Pharmaceuticals, Inc. Icon Bioscience, Inc. EyeGene, Inc. Varinel, Inc. For more information visit http://www.researchandmarkets.com/research/wv3x9q/macula About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
OTC Daily Alert Stock Watch - Lpath, Inc., (NASDAQ: LPTN)
WorldStockWire - Fri Aug 30, 12:15AM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
Traumatic Brain Injury - Pipeline Review, H1 2014: Includes 42 Company and 72 Drug Profiles
M2 - Mon May 12, 5:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vqxgvm/traumatic_brain) has announced the addition of the "Traumatic Brain Injury - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Traumatic Brain Injury, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Traumatic Brain Injury and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved: - ALSP, Inc. - Acorda Therapeutics, Inc. - Adamas Pharmaceuticals, Inc. - Allinky Biopharma - Amarantus Bioscience Holdings, Inc. - Athersys, Inc. - BHR Pharma, LLC - Bionature E.A. Ltd. - Cognosci, Inc. - Concert Pharmaceuticals, Inc. - D-Pharm Ltd. - Encore Therapeutics Inc. - Euroscreen S.A. - Grupo Ferrer Internacional, S.A. - Intellect Neurosciences, Inc. - Io Therapeutics, Inc. - Lixte Biotechnology Holdings, Inc. - Lpath, Inc. - M's Science Corporation - MAPREG - MandalMed, Inc. - Mnemosyne Pharmaceuticals, Inc. - NeoStem, Inc. - Neuralstem, Inc. - Neuren Pharmaceuticals Limited - NeuroHealing Pharmaceuticals Inc. - NeuroNascent, Inc. - NeuroVive Pharmaceutical AB - Omeros Corporation - Oxygen Biotherapeutics, Inc. Drug Profiles: - epoetin alfa - progesterone - progesterone - NeuroSTAT - Oxycyte - VAS-203 - NH-001 - NNZ-2566 - atorvastatin calcium - NeuroSTAT - glyburide - Allopregnanolone - VOLT-02 - SB-623 - RGS-2064 - DP-b99 - amantadine hydrochloride - Drug for Traumatic Brain Injury - MAP-4343 - Posiphen - MultiStem - Lpathomab - RGN-352 - cutamesine - INN-01 - NSI-189 - COG-1410 - AMR-001 - NSI-566 - LB-201 For more information visit http://www.researchandmarkets.com/research/vq...atic_brain
Lpath announces Fast-Track SBIR grant for IND-enabling studies of Lpathomab for Traumatic Brain Injury
M2 - Mon May 05, 8:14AM CDT
Antibody-platform company Lpath Inc (NasdaqCM:LPTN) said on Monday that it will receive a USD1.7m, 2.5-year grant to develop its antibody therapeutic, Lpathomab, which is directed against the bioactive lipid lysophosphatidic acid (LPA) for the treatment of traumatic brain injury (TBI).
Lpath Lands Fast-Track SBIR Grant from the NIH for Traumatic Brain Injury Treatment
PR Newswire - Mon May 05, 6:30AM CDT
Lpath, Inc. (NASDAQ: LPTN), the industry leader in bioactive lipid-targeted therapeutics, received official notification from the National Institutes of Neurological Diseases and Stroke (NINDS) that it has been awarded a $1.7 million, 2.5-year grant to develop its antibody therapeutic, Lpathomab(TM), which is directed against the bioactive lipid lysophosphatidic acid (LPA) for the treatment of traumatic brain injury (TBI).
Global Colitis Therapeutics Pipeline Review 2014 - Analysis of 16 Companies & 32 Drug Profiles
M2 - Tue Apr 29, 8:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3zwv5t/colitis) has announced the addition of the "Colitis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Colitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Colitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Colitis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Colitis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Colitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Colitis pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Colitis - Companies Involved in Therapeutics Development - Inovio Pharmaceuticals, Inc. - BioLineRx, Ltd. - Pfizer Inc. - Idera Pharmaceuticals, Inc. - Lpath, Inc. - Protalix BioTherapeutics, Inc. - Galapagos NV - Akebia Therapeutics, Inc. - NasVax Ltd. - Lycera Corp. - Zyngenia, Inc. - N30 Pharmaceuticals - Cognosci, Inc. - Atlantic Healthcare Limited - CellAct Pharma GmbH - Ajinomoto Pharmaceuticals Co., Ltd. Drug Profiles - LT-1009 - PF-06425090 - IMO-3100 - BL-5040 - VGX-1027 - N-6022 - GLPG-0634 - COG-112 - Anti-CD3 Oral Immunotherapy - etanercept biosimilar - N-6547 - BRA-101 - Bioenergetics Program - ARA-290 - CAP-2.1 - CAP-2.2 - Clostridium difficile Vaccine - Cathelicidin - IP-1510 - Helminth-Derived Peptides - Drugs to Inhibit Panx1 for Colitis - Recombinant Cholera Toxin-B - Bi-Specific Anti-TNFalpha/Ang2 Zybody - auranofin - NK-007 - Treg Cells to Inhibit TCR Antagonist for Colitis - Vaccine for Colitis and Respiratory Tract Inflammatory Disorders - APY-0201 - IL-23 P19 Vaccine - AKB-6899 For more information visit http://www.researchandmarkets.com/research/3zwv5t/colitis
Global Diabetic Neuropathy Therapeutic Pipeline Review 2014 - 11 Companies and 18 Drugs Profiled
M2 - Mon Apr 28, 2:56AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8552ww/diabetic) has announced the addition of the "Global Diabetic Neuropathy Therapeutic Pipeline Review 2014 - 11 Companies and 18 Drugs Profiled" report to their offering. This report provides comprehensive information on the therapeutic development for Diabetic Neuropathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Neuropathy and special features on late-stage and discontinued projects.The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. Scope: - The report provides a snapshot of the global therapeutic landscape of Diabetic Neuropathy - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Diabetic Neuropathy and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Diabetic Neuropathy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages Companies Involved in Therapeutics Development: - Dainippon Sumitomo Pharma Co., Ltd. - Neuralstem, Inc. - Lpath, Inc. - DiaMedica Inc. - R-Tech Ueno, Ltd. - Neurotune AG - Intellect Neurosciences, Inc. - Glucox Biotech AB - Vascular Pharmaceuticals, Inc. - Relmada Therapeutics, Inc. - Dong-A Socio Holdings Co Ltd Drug Profiles: - ranirestat - ranirestat - DA-3030 - DA-9801 - atexakin alfa - Lpathomab - NT-13317 - RTU-1096 - INN-01 - NSI-566 - mepivacaine hydrochloride - Stromal Cell Therapy For Diabetic Complications - VPI-2690-B - Angiotensin (1-7) peptide - Small Molecule For Diabetic Neuropathy And Retinopathy - DM-433 - Small Molecule To Inhibit NOX-4 For Diabetic Neuropathy - BBI-21007 For more information visit http://www.researchandmarkets.com/research/8552ww/diabetic
Lpath and Walter Reed Army Institute for Research Begin Efficacy Study Using Lpathomab in Traumatic Brain Injury Models
PR Newswire - Wed Apr 23, 6:30AM CDT
Lpath, Inc. (NASDAQ: LPTN), the industry leader in bioactive lipid-targeted therapeutics, and scientists from the Center for Military Psychiatry and Neuroscience, Walter Reed Army Institute of Research (WRAIR), have initiated a study that is the focus of a collaborative research agreement.
3 Stocks Under $10 to Watch
at The Street - Mon Mar 17, 6:40AM CDT
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
Nasdaq stocks posting largest volume increases
AP - Thu Mar 06, 5:07PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
New Published Paper Shows Efficacy of Lpath's Anti-LPA Antibody, Lpathomab, in Traumatic Brain Injury Models
PR Newswire - Wed Mar 05, 6:30AM CST
Lpath, Inc. (NASDAQ: LPTN), the industry leader in bioactive lipid-targeted therapeutics, has brought scientists one step closer to finding a potential treatment for traumatic brain injury (TBI) with a recent publication showing that Lpathomab(TM), a therapeutic antibody, reverses much of the damage caused by trauma to the nervous system.
Lpath to Present at Upcoming Roth Investor Conference
PR Newswire - Tue Mar 04, 7:00AM CST
Lpath, Inc. (NASDAQ: LPTN), the industry leader in bioactive lipid-targeted therapeutics, today announced that Scott Pancoast, president and CEO, will be presenting at the 26th Annual Roth Conference being held March 10 -12, 2014 in Laguna Niguel, Calif. Mr. Pancoast is scheduled to present on March 11, 2014 at 4:30 p.m. PST/7:30 p.m. EST. The presentation will be webcast live and will be available for replay on the Lpath, Inc. corporate website at www.Lpath.com.
Lpath announces receipt of key US patent related to its ocular drug programme
M2 - Thu Jan 23, 5:03AM CST
Lpath Inc (Nasdaq:LPTN), a provider of bioactive lipid-targeted therapeutics, announced on Wednesday the receipt of official notification from the US Patent and Trademark Office that it has been issued another key patent supporting its iSONEP programme.
Lpath Granted Key U.S. Patent Related to Ocular Drug Program, iSONEP
PR Newswire - Wed Jan 22, 6:30AM CST
Lpath, Inc. (NASDAQ: LPTN), the industry leader in bioactive lipid-targeted therapeutics, received official notification from the U.S. Patent and Trademark Office that the company has been issued another key patent supporting its iSONEP(TM) program. The newly issued U.S. patent, No. 8,614,103, is entitled, "Compositions and Methods for Treating Ocular Conditions." It claims methods of using monoclonal antibodies (including iSONEP) that bind sphingosine-1-phosphate (S1P) in the treatment of a wide variety of ocular conditions, including wet age-related macular degeneration (AMD).
FEPSGA Games - Herbalist, Others Enjoy Trade Boom in Makurdi
All Africa Global Media - Wed Dec 18, 4:41AM CST
A herbalist selling traditional medicines at the venue of the ongoing Federal Public Service Games Association (FEPSGA) Games in Makurdi says he is enjoying high patronage.
Global Pulmonary Fibrosis Pipeline Review Report - H2 2013 Edition Now Available
M2 - Tue Dec 17, 10:01AM CST
Research and Markets (http://www.researchandmarkets.com/research/cqb72k/pulmonary) has announced the addition of the "Pulmonary Fibrosis - Pipeline Review, H2 2013" report to their offering. 'Pulmonary Fibrosis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Pulmonary Fibrosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Pulmonary Fibrosis. Scope - A snapshot of the global therapeutic scenario for Pulmonary Fibrosis. - A review of the Pulmonary Fibrosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Pulmonary Fibrosis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Involved in Pulmonary Fibrosis Therapeutics Development - Eli Lilly and Company - Lpath, Inc. - Mesoblast Ltd - NicOx SA - Oncothyreon Inc - Pharmaxis Ltd. - Paloma Pharmaceuticals, Inc. - Digna Biotech, S.L. - Aquinox Pharmaceuticals Inc. - Angion Biomedica Corp. - Centocor Ortho Biotech, Inc. - Fibrotech Therapeutics Pty. Ltd. - FCB-Pharmicell Co.,Ltd. - Clarassance, Inc. Drug Profiles - Lpathomab - P-17 - AZX-100 - PX-866 - STNM-04 - P-529 - AQX-1125 - Btx-201 - GR-MD-02 - ICG-001 - CG-1011 - ANG-3298 - C-201 - Galectin-3 Inhibitors - SDP-051 - FT-011 - CT-140 - PDE-4A4 Inhibitors - NCX-466 - MC-1575 - Lungcellgram - CpG Oligonucleotides - PXS-5033-A For more information visit http://www.researchandmarkets.com/research/cqb72k/pulmonary
Lpath Withdraws From Pfizer's Process to Assign iSONEP Rights
PR Newswire - Thu Dec 12, 6:00AM CST
Lpath, Inc. (Nasdaq: LPTN), the category leader in lipid-targeted therapeutics, is no longer actively participating in Pfizer's process to assign the exclusive option it has for a worldwide license to develop and commercialize Lpath's iSONEP(TM). Pfizer has informed Lpath that its offers were not competitive with other offers.
Lpath Announces New Antibody Program, Altepan(TM), Targeting Respiratory Disease
PR Newswire - Thu Nov 21, 6:00AM CST
Lpath, Inc. (Nasdaq: LPTN), the category leader in lipid-targeted therapeutics, has used its proprietary discovery technology to generate several monoclonal antibody product candidates targeting the leukotriene family of bioactive lipids. Leukotrienes are implicated in numerous inflammatory processes. The lead antibody, which binds to and neutralizes several different leukotriene isoforms, has shown positive in vivo results, and testing in animal models of respiratory disease, including asthma, is now underway.
Macular Degeneration - Pipeline Review, H2 2013 Gives an Overview of Pipeline Products for Macular Degeneration
M2 - Wed Sep 04, 12:19PM CDT
Research and Markets (http://www.researchandmarkets.com/research/wv3x9q/macular) has announced the addition of the "Macular Degeneration - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Macular Degeneration - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Macular Degeneration, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Macular Degeneration. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Macular Degeneration. - A review of the Macular Degeneration products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Macular Degeneration pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: Normal 0 false false false MicrosoftInternetExplorer4 Alcon, Inc. Genzyme Corporation Johnson & Johnson F. Hoffmann-La Roche Ltd. Bausch & Lomb Incorporated Allergan, Inc. Shionogi & Co., Ltd. pSivida Corp. Advanced Cell Technology, Inc. GlaxoSmithKline plc Genentech, Inc. Quark Pharmaceuticals, Inc. Pfizer Inc. iCo Therapeutics Inc. Lpath, Inc. Mesoblast Ltd BioDiem Ltd Summit Corporation plc ThromboGenics NV PolyMedix, Inc. e-Therapeutics plc NanoCarrier Co., Ltd. R-Tech Ueno, Ltd. Intellect Neurosciences, Inc. Omeros Corporation Angstrom Pharmaceuticals, Inc. Targa Therapeutics Corp. Pfenex Inc. SelectX Pharmaceuticals, Inc. Icon Bioscience, Inc. EyeGene, Inc. Varinel, Inc. For more information visit http://www.researchandmarkets.com/research/wv3x9q/macula About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
OTC Daily Alert Stock Watch - Lpath, Inc., (NASDAQ: LPTN)
WorldStockWire - Fri Aug 30, 12:15AM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
